ArticlePLoS biology2017
Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1.
Article in PLoS biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials.European journal of clinical pharmacology · 2020Pooled it
- Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis.Cancer medicine · 2019Pooled it
- Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer.Molecular oncology · 2019Trial
- Chronic hypoxia induces liver injury via PKCδ/ASMase-driven ceramide accumulation and endoplasmic reticulum stress in rats.Lipids in health and disease · 2025Article
- Pharmacologic Potential of Statins in Cancer Prevention: Colo-Rectal Cancer Risk in Dyslipidemic Patients from a Korean Nationwide Cohort.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A Critical Appraisal of Off-Label Use and Repurposing of Statins for Non-Cardiovascular Indications: A Systematic Mini-Update and Regulatory Analysis.Journal of clinical medicine · 2025Article
- Novel High-Throughput Screen Identified S100A4 Inhibitors for Anti-Metastatic Therapy.International journal of biological sciences · 2025Article
- MACC1 revisited - an in-depth review of a master of metastasis.Biomarker research · 2024Review
- Cholesterol synthesis is essential for the growth of liver metastasis-prone colorectal cancer cells.Cancer science · 2024Article
- Immune Response and Metastasis-Links between the Metastasis Driver MACC1 and Cancer Immune Escape Strategies.Cancers · 2024Review
- Sulfotransferase SULT2B1 facilitates colon cancer metastasis by promoting SCD1-mediated lipid metabolism.Clinical and translational medicine · 2024Article
- Article
- Article
- Article
- Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer.Frontiers in oncology · 2023Article
- miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway.Journal of hepatocellular carcinoma · 2023Article
- Refined control of CRISPR-Cas9 gene editing inFrontiers in immunology · 2023Article
- MACC1-induced migration in tumors: Current state and perspective.Frontiers in oncology · 2023Review
- Identification of Hub Genes for Colorectal Cancer with Liver Metastasis Using miRNA-mRNA Network.Disease markers · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MACC1 (Metastasis Associated in Colon Cancer 1) is a key driver and prognostic biomarker for cancer progression and metastasis in a large variety of solid tumor types, particularly colorectal cancer (CRC). However, no MACC1 inhibitors have been identified yet. Therefore, we aimed to target MACC1 expression using a luciferase reporter-based high-throughput screening with the ChemBioNet library of more than 30,000 compounds. The small molecules lovastatin and rottlerin emerged as the most potent MACC1 transcriptional inhibitors. They remarkably inhibited MACC1 promoter activity and expression, resulting in reduced cell motility. Lovastatin impaired the binding of the transcription factors c-Jun and Sp1 to the MACC1 promoter, thereby inhibiting MACC1 transcription. Most importantly, in CRC-xenografted mice, lovastatin and rottlerin restricted MACC1 expression and liver metastasis. This is-to the best of our knowledge-the first identification of inhibitors restricting cancer progression and metastasis via the novel target MACC1. This drug repositioning might be of therapeutic value for CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.